BEVERLY, MA--(Marketwire - April 21, 2010) - Cellceutix Corporation (
"These data are another important piece of the Kevetrin story," said its Chief Scientific Officer, Dr. Krishna Menon. "The continued and undiminished anti-tumor effect when a second cycle is administered is particularly significant, showing that resistance to Kevetrin is not developing."
The experiment consisted of five groups of animals: controls, Kevetrin 50 mg/kg, Kevetrin 100 mg/kg and Kevetrin 200 mg/kg. In the 50 mg/kg, 100 mg/kg, and 200 mg/kg groups, Kevetrin was administered in three doses every other day. In an additional group, 200 mg/kg Kevetrin was administered in three doses every other day followed by a second cycle administered 10 days after the first cycle. The 100 mg/kg and 200 mg/kg Kevetrin groups (one or two cycles) showed significant delays in tumor growth compared to controls. In addition, tumor growth delay with Kevetrin was dose dependent. No resistance was observed with the second cycle of Kevetrin.
"We are extremely pleased to be able to present these important new data at AACR," said George Evans, CEO of Cellceutix. "These data again show strong activity in a resistant lung cancer cell line and the fact that Kevetrin delays tumor growth in a dose dependent manner is important as we move toward a phase 1 human trial."
More information about Kevetrin and the rest of the Cellceutix portfolio is available on the Cellceutix web site at www.cellceutix.com.
About Cellceutix
Cellceutix Corporation is a preclinical cancer and anti-inflammatory drug developer. Cellceutix owns the rights to eight drug compounds, including Kevetrin, which it is developing as a treatment for certain cancers, and KM-391, which it is developing for the treatment of autism. More information is available on the Cellceutix web site at www.cellceutix.com.
This Press Release contains forward-looking statements that are based on our current expectations, beliefs and assumptions about the industry and markets in which Cellceutix Corporation operates. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause Cellceutix's actual results to be materially different from any future results expressed or implied by these statements. Actual results may differ materially from what is expressed in these statements, and no assurance can be given that Cellceutix can successfully implement its core business strategy and improve future earnings. The factors that may cause Cellceutix's actual results to differ from its forward-looking statements include: Cellceutix's current critical need for additional cash to sustain existing operations and meet ongoing existing obligations and capital requirements; Cellceutix's ability to implement its new product development and commercialization, enter into clinical trials, expand the intellectual property portfolio, and receive regulatory approvals in a timely and cost-effective manner. All forward-looking statements are also expressly qualified in their entirety by the cautionary statements included in Cellceutix's SEC filings, including its quarterly reports on Form 10-Q and its annual report on Form 10-K.
Kevetrin and KM-391 have not been studied in humans at this time. The Company's positive results in animal studies do not necessarily guarantee success in humans, though they may form the basis for beginning Phase 1 trials.
Contact Information:
Contact:
Cellceutix Corp.
Leo Ehrlich
(978) 633-3623